This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

Tipranks - Tipranks - Thu Jul 9, 3:50AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO).

55% Off TipRanks

Tvardi Therapeutics (TVRD)

Barclays analyst Etzer Darout maintained a Sell rating on Tvardi Therapeutics today and set a price target of $3.00. The company’s shares closed last Tuesday at $3.10, close to its 52-week low of $2.71.

According to TipRanks.com, Darout is a top 100 analyst with an average return of 32.0% and a 64.1% success rate. Darout covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Monopar Therapeutics Inc, and Iovance Biotherapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tvardi Therapeutics with a $9.80 average price target, implying a 360.1% upside from current levels. In a report issued on June 27, TipRanks – DeepSeek also downgraded the stock to Sell with a $1.50 price target.

See Insiders’ Hot Stocks on TipRanks >>

Teva Pharmaceutical (TEVA)

In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Teva Pharmaceutical, with a price target of $40.00. The company’s shares closed last Tuesday at $34.65.

According to TipRanks.com, Santangelo is a 4-star analyst with an average return of 5.3% and a 55.8% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Amphastar Pharmaceuticals, and Bausch Health Companies. ;'>

Teva Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $42.38, representing a 20.4% upside. In a report issued on June 26, UBS also maintained a Buy rating on the stock with a $42.00 price target.

BridgeBio Pharma (BBIO)

In a report released today, Eliana Merle from Barclays maintained a Buy rating on BridgeBio Pharma, with a price target of $157.00. The company’s shares closed last Tuesday at $77.91.

According to TipRanks.com, Merle is a 4-star analyst with an average return of 7.1% and a 52.3% success rate. Merle covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and BioMarin Pharmaceutical. ;'>

Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $106.22, a 36.1% upside from current levels. In a report issued on June 27, TipRanks – Google also upgraded the stock to Buy with a $77.00 price target.

Read More on TVRD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).